Infliximab reduces oxidative stress in ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 27, Issue 1, 2009, Pages 167-168

  Feijoo M ^a   Túnez, Isaac ^a   Tasset, I ^a   Montilla, P ^b   Ruiz, A ^b   Collantes, E ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INFLIXIMAB; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ADULT; ANKYLOSING SPONDYLITIS; ANTIOXIDANT ACTIVITY; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LETTER; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDASE; PILOT PROJECTS; PROTEIN CARBONYLATION; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 63049103937     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. KAGEYAMA Y, TAKAHASHI M, ICHIKAWA T, TORIKAI E, NAGANO A: Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 73-80.
2. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 37: 361-8.
3. BRAUN J, DAVIS J, DOUGADOS M et al.: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-20.
4. LEVINE RL, GARLAND D, OLIVER CN et al.: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990; 1186: 464-78.
5. FLOHÉ L, GÜNZLER WA: Assays of glutathione peroxidase. Methods Enzymol 1984; 105: 114-21
6. AEBI H: Catalase in vitro. Methods Enzymol 1984; 105: 121-6.
7. SUN Y, OBERLEY LW, LI Y: A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 479-500.
8. LEMARECHAL H, ALLANORE Y, CHENEVIER-GOBEAUX C, KAHAN A, EKINDJIAN OG, BORDERIE D: Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab. Clin Chim Acta 2006; 372: 147-53.
9. TUNEZ I, FEIJOO M, HUERTA G et al.: The effect of infliximab on oxidative stress in chronic inflammatory joint disease. Curr Med Res Opin 2007; 23: 1259-67.
10. YAZICI C, KÖSE K, CALIS M, KUZUGÜDEN S, KIRNAP M: Protein oxidation status in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 43: 1235-39.
11. OZGOCMEN S, SOGUT S, ARDICOGLU O, FADILLIOGLU E, PEKKUTUCU I, AKYOL O: Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis. Rheumatol Int 2004; 24: 80-3.